Revvity Signals - Drug Discovery

Pharmaceutical interfaces: Drug development, performance, regulation and e-health

Authors : Diane J. Burgess

Interfaces play a crucial role in bioactive delivery, impacting stability and various other aspects. This presentation delves into different interfaces within the delivery system, including those with body tissues, regulatory bodies, and the emerging field of e-health applications. Basic science principles and discussions on e-health will be covered.

Formulations encompass interfaces between different phases, such as emulsions, foams, and suspensions. Interfaces between active ingredients and excipients are also significant, especially when they exist in different states. Weaknesses within these interfaces can lead to stability concerns, caused by phase changes and compatibility issues like hydrophilicity/lipophilicity discrepancies.

The interface between the body and the delivery system varies depending on the dosage form and administration route. The tissue/device interface influences the foreign body response and its implications. Additionally, the interface between the industry and regulatory authorities is crucial for understanding device performance testing and safety measures.

In the era of e-health, comprehending the impact on drug delivery science is essential. This presentation focuses on four key aspects: 1) formulation challenges related to interface stability; 2) overcoming the foreign body response in drug delivery devices; 3) interface considerations with regulatory authorities for controlled release parenteral products; and 4) exploring the interface between drug delivery and e-health advancements.

Peer review under responsibility of Shenyang Pharmaceutical University.

Keywords

Pharmaceutical interfaces; Drug development; E-health

Citation: Diane J. Burgess Pharmaceutical interfaces: Drug development, performance, regulation and e-health doi:10.1016/j.ajps.2015.10.003

Available online 5 November 2015

Copyright: © 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)